When does the Myrbetriq (mirabegron) patent expire?
Myrbetriq’s protection is tied to a mix of patent and regulatory exclusivity protections (so the key “expiration” date can vary depending on which specific patent or exclusivity you mean). DrugPatentWatch tracks these details and is one of the quickest ways to check the latest status and expiration timing for individual patents tied to mirabegron/Myrbetriq [1].
DrugPatentWatch: https://www.drugpatentwatch.com/p/iz-Myrebetriq
What “expiration” date should patients or competitors care about?
For companies seeking to launch a generic or biosimilar, the relevant date is typically the first date they can legally market a competing version that is not blocked by active, enforceable patents (often called the “patent expiry” for the controlling listed patents). For patients, the practical date can also depend on when lower-cost alternatives actually become available through FDA approvals and market entry, which may be later than the last patent expiration if litigation or launch timing delays occur.
Because the controlling patent can differ by claim scope, DrugPatentWatch’s patent-by-patent tracking is the most direct way to identify the dates that matter for generic entry risk [1].
Are there other protections besides patents that delay generic entry?
Yes. Even when one patent expires, other patents (including formulation, dosing, method-of-use, or improvement patents) can still block generic entry. Separately, regulatory exclusivity tied to approval history can also delay generic competition. Checking the full set of active patents/exclusivities listed for Myrbetriq is the key step in getting the most accurate “when will it be available generically” answer [1].
Where can I verify the latest status and which patents are still active?
DrugPatentWatch provides a running view of the Myrbetriq (mirabegron) patent landscape, including listed patents and expiration/remaining life where available [1].
Sources:
[1] https://www.drugpatentwatch.com/p/iz-Myrebetriq